After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.
Four months after securing $125 million in funding, SpringWorks Therapeutics is eying another $115 million from a potential initial public offering.
